Open Hours Events

Career Opportunities
2008
11th November
Kernel Investee Company Merrion Pharma signs License Agreement with Nova Nordisk up to US$58m
11th November
Kernel Capital Investee Company Merrion Pharma receives prestigious Frost & Sullivan Award
29th September
Merrion Pharma moves to next stage of drug research programme with Nova Nordisk
12th June
MPSTOR Announces OEM licensing contract with leading storage Manufacturer, AIC Inc, Los Angeles
25th April
Kernel Capital Investee Company ChipSensors Ltd receives prestigious endorsements
18th March
Kernel Capital confirm Dr Jim Walsh as Advisor
22nd February
Kernel Capital announces Dr. Daniel O’ Mahony Ph.D; M.Sc as Partner
Merrion Pharma moves to next stage of drug research programme with Nova Nordisk

September 29, 2008: Merrion Pharmaceuticals Plc. said it has started the next stage of an oral drug delivery research collaboration programme with Novo Nordisk. This follows completion of several oral feasibility studies combining Merrion's Gastrointestinal Permeation Enhancement Technology (GIPET) oral drug delivery technology with Novo Nordisk compounds. In continuation of this collaboration, Merrion will now complete the development of solid dosage forms with GIPET for additional testing, the company said.


Kernel Management Partners Limited, trading as Kernel Capital, is regulated by the Central Bank of Ireland.